Company Profile
Celcuity Stock Price, News & Analysis
- Ticker:
- CELC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
93.25 USD (+0.36%)
Close
Last updated: August 6, 2026
4.46B USD
Market cap
Why the stock is moving
The latest company update was “Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call”. CELC changed 0.36% and closed at $93.25 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
PAM Pathway-Targeted Oncology Company
Celcuity develops targeted therapies for solid tumors. Lead candidate gedatolisib is a PI3K/AKT/mTOR pathway inhibitor that simultaneously targets all class I PI3K isoforms, mTORC1, and mTORC2.
Gedatolisib in Breast Cancer
The Phase 3 VIKTORIA-1 study evaluates gedatolisib with fulvestrant, with or without palbociclib, in HR-positive, HER2-negative advanced breast cancer. The company has reported positive results in both PIK3CA wild-type and mutant cohorts in the second-line setting.
Multi-Node Pathway Inhibition
Unlike agents that inhibit a single PI3K isoform or one downstream target, gedatolisib is designed to suppress several nodes across the PAM pathway. Celcuity is testing whether this broader inhibition can address pathway feedback and resistance mechanisms in advanced breast cancer.
First-Line and Formulation Expansion
VIKTORIA-2 is evaluating gedatolisib combinations as first-line therapy in advanced breast cancer through separate endocrine-resistant and endocrine-sensitive studies. Celcuity is also developing a subcutaneous formulation of gedatolisib.
Transition Toward Commercialization
Positive late-stage evidence in second-line breast cancer is moving Celcuity toward a potential first product launch. The company is building commercial capabilities while continuing studies intended to broaden treatment settings and simplify administration.
Future catalysts
Detailed results for the gedatolisib triplet and doublet regimens in the PIK3CA-mutant cohort of VIKTORIA-1 were scheduled for presentation at the 2026 ASCO Annual Meeting.
Celcuity is advancing commercial preparation ahead of a potential FDA approval of gedatolisib in the third quarter of 2026.
VIKTORIA-2 has expanded into first-line endocrine-sensitive HR-positive, HER2-negative advanced breast cancer, with future enrollment and data representing the key milestone for moving the program earlier in treatment.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Celcuity (CELC)?
Celcuity (CELC) most recently closed at 93.25 USD, a +0.36% move versus the previous session.
What is the market cap of Celcuity (CELC)?
Celcuity currently has a market capitalization of 4.46B USD on BioPharmSignal.
What does Celcuity do?
PAM Pathway-Targeted Oncology Company Celcuity develops targeted therapies for solid tumors. Lead candidate gedatolisib is a PI3K/AKT/mTOR pathway inhibitor that simultaneously targets all class I PI3K isoforms, mTORC1, and mTORC2. Gedatolisib in Breast Cancer The Phase 3 VIKTORIA-1 study evaluates gedatolisib with fulvestrant, with or without palbociclib,...
On which exchange is CELC stock listed?
Celcuity (CELC) is associated with NASDAQ, United States, Biopharma.
What is VIKTORIA-1?
Detailed results for the gedatolisib triplet and doublet regimens in the PIK3CA-mutant cohort of VIKTORIA-1 were scheduled for presentation at the 2026 ASCO Annual Meeting.
Which conditions is Celcuity targeting with VIKTORIA-1?
Celcuity is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Celcuity describe recent progress with VIKTORIA-1?
Detailed results for the gedatolisib triplet and doublet regimens in the PIK3CA-mutant cohort of VIKTORIA-1 were scheduled for presentation at the 2026 ASCO Annual Meeting.
What is VIKTORIA-2?
First-Line and Formulation Expansion VIKTORIA-2 is evaluating gedatolisib combinations as first-line therapy in advanced breast cancer through separate endocrine-resistant and endocrine-sensitive studies.